Physician profile
Sharon Thrush
NPI 1669456794
$2,704.77
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,322 · 2022: $783 · 2023: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $534.57 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $473.73 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $265.19 | 2021-2023 | |
| Novo Nordisk INC | $189.93 | 2021-2023 | Rybelsus, Wegovy, Ozempic |
| Pfizer INC. | $169.10 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $101.37 | 2021-2023 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $95.47 | 2021-2022 | |
| Exact Sciences Corporation | $81.62 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.49 | 2021-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $75.44 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.40 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $74.23 | 2023 | Quviviq |
| Amgen INC. | $72.68 | 2021-2022 | |
| Abbott Laboratories | $70.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.25 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $48.15 | 2022 | |
| Eisai INC. | $42.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.26 | 2022 | |
| Amarin Pharma, INC. | $36.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $28.82 | 2021-2022 | |
| Astellas Pharma US INC | $22.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.58 | 2022 | |
| Lucid Diagnostics INC. | $14.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Thrush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.